Incannex Healthcare Inc. (IXHL) Stock Price & Analysis

Incannex Healthcare Inc. (IXHL) fell 0.15% to USD 3.25 as of September 8, 2026 at 10:52 UTC, according to Nexqual real-time market data.

IXHL last closed at USD 3.25; the session ranged USD 3.22–3.31 on volume of 45,854 shares. Market capitalization is —, with a 52-week range of USD 2.49–20.31 (NCM). Source: Nexqual, September 8, 2026 at 10:52 UTC.

Key Statistics (as of September 8, 2026 at 10:52 UTC)

Technical Analysis (IXHL)

Nexqual's technical model rates IXHL "SELL" based on 2 bullish and 4 bearish signals across 128 daily candles, as of September 8, 2026 at 10:52 UTC.

From Incannex Healthcare Inc.'s Latest SEC 10-K Filing (filed 2025-09-29)

Key Strengths & Strategy (as disclosed to the SEC)

• Food and Drug Administration (the "FDA") to obtain guidance on planned next steps, including a pivotal Phase 3 trial design.   PSX-001, our drug candidate in Phase 2 clinical development, is an oral synthetic psilocybin treatment, administered in combination with psychological therapy for patients with moderate-to-severe generalized anxiety disorder ("GAD").
• FDA approval is required before any new drug, including any new indication for a previously approved drug, can be marketed in the United States.   The steps required before a drug may be marketed in the United States generally include the following:       14                     Clinical Development   Before any drug candidate may be tested in humans, it must undergo rigorous preclinical testing.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 10:52 UTC. This page is informational and not investment advice.